JPMorgan Starts Neumora Therapeutics (NMRA) at Overweight, 'a Plethora of Optionality'
Tweet Send to a Friend
(Updated - October 10, 2023 4:49 AM EDT)
JPMorgan analyst Tessa Romero initiates coverage on Neumora Therapeutics (NASDAQ: NMRA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero initiates coverage on Neumora Therapeutics (NASDAQ: NMRA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
